R&D Cost Accounting for Biotech Companies: A Practical Guide (ASC 730 Explained)

For most life science companies, R&D costs dominate the income statement; often representing the majority of operating expenditure long before a product reaches market. Many companies only discover problems in their R&D reporting when investors, auditors, or acquirers start asking questions. The decisions you make about how to classify, track, and report these costs shape your financial statements, your investor narrative, and your readiness for a fundraising round or an exit.

This guide covers the core principles of R&D cost accounting under U.S. GAAP, the areas where life science companies most commonly encounter complexity, and why getting this right matters beyond compliance. For a broader look at the financial challenges life science companies face at every stage, see our Biotech Industry Accounting Guide.

The Foundational Rule: ASC 730

The governing standard for R&D accounting under U.S. GAAP is ASC 730, which requires that most R&D costs be expensed as incurred rather than capitalized as assets on the balance sheet. The rationale is that the future economic benefits of R&D activities are too uncertain to justify treating those costs as long-lived assets.

For life science companies, this has a practical implication worth stating plainly: significant operating losses on your income statement reflect the nature of the business, not its trajectory. Sophisticated investors in the sector understand this, and they evaluate companies on metrics such as cash runway, program milestones, and pipeline value rather than near-term profitability.

A carve-out worth knowing: acquired in-process R&D (also known as IPR&D) — R&D assets purchased through a business combination — is generally capitalized at fair value rather than expensed immediately, and subsequently tested for impairment.

What Activities Are Classified as R&D in Life Sciences?

Misclassification of R&D costs is one of the most common accounting issues in life sciences, and it tends to surface at the worst possible moments: during fundraising diligence, ahead of an audit, or in the middle of an M&A process. The key is a clear, consistently applied framework for what qualifies.

Under ASC 730, R&D encompasses activities aimed at discovering new knowledge or translating that knowledge into new or significantly improved products, processes, or services. In practice, this includes drug discovery and preclinical studies, clinical trial costs (including CRO fees, investigator payments, and patient enrollment expenses), medical device prototyping and design validation, and regulatory testing required for FDA approval or clearance.

Some activities require judgment. Formulation development and process optimization studies may qualify depending on whether they're advancing novel science or refining established processes. Other costs fall outside ASC 730 entirely, including post-approval manufacturing improvements, routine quality testing, and sales and marketing activities for approved products.

Misclassification in either direction creates problems. Understating R&D expenses can inflate apparent profitability and invite regulatory scrutiny. Overstating them can obscure true operating cost structures. Either way, inconsistency erodes credibility with investors and auditors alike.

Clinical Trial Accrual Accounting: The Highest-Stakes Challenge

For most life science companies, clinical trial costs represent the largest and most complex component of R&D spending. The key challenge in clinical trial accounting is timing: costs must be recognized in the period when services are performed, not when invoices arrive or payments are made.

This matters because CROs and clinical sites typically invoice on milestone or periodic payment schedules that don't align with actual activity. Consider a straightforward example: if a CRO invoices $2 million for a clinical trial milestone but only 40% of patient visits have occurred by quarter-end, the company should recognize roughly $800,000 of expense rather than the full invoice amount. Booking the full $2 million overstates expenses for that period and understates them in future periods, producing swings in reported results that have nothing to do with underlying scientific progress.

The solution is a robust monthly accrual process that incorporates real-time data on patient enrollment status, site activation milestones, and investigator activity. Companies that build this discipline early produce financials that hold up under investor scrutiny and reduce the risk of material restatements. Accrual discipline is ultimately an investor relations issue as much as an accounting one — unexpected swings in reported expenses can prompt questions about financial controls that distract from the scientific story you're trying to tell.

Program-Level Tracking

A single R&D line item on your income statement tells investors very little. What they want to understand as part of their due diligence process is the financial profile of each program: how much capital has been invested, what milestones that spending has achieved, and how much additional investment will be required to reach the next value inflection point.

Program-level cost tracking translates R&D spending into a strategic narrative. In practice, this means allocating CRO and clinical costs by protocol, separating platform R&D from program-specific spend, and tracking expenditure by clinical phase. It gives management clear visibility into resource allocation across the portfolio, supports more accurate forecasting, and provides the granular data that investors and acquirers rely on when modeling program value. Companies that invest in this infrastructure early find it pays off significantly when it comes time to raise capital or engage in a transaction.

Grant Funding: A Policy Choice with Real Consequences

SBIR, STTR, NIH, and foundation grants are a meaningful funding source for many early-stage life science companies. U.S. GAAP does not prescribe a single accounting treatment for these awards, which means companies face a genuine accounting policy choice: recognize grant proceeds as revenue, or record them as a reduction of R&D expense.

Each approach produces different reported margins and operating metrics. Recognizing grants as revenue inflates the top line and can make the company appear closer to commercial operations than it is. Recording them as an expense reduction produces lower reported R&D costs, which may understate true program investment. Neither is inherently wrong, but the choice should be made deliberately, documented clearly, and applied consistently.

Federal grants also carry compliance requirements that affect how costs are tracked and reported. NIH grants, for example, require detailed documentation of how funds are deployed against approved budget categories — which reinforces the value of program-level tracking systems that can support both financial reporting and grant compliance simultaneously.

Building a Foundation That Holds Up

R&D cost accounting in life sciences is not just a compliance function. The decisions you make about expense classification, accrual processes, program tracking, and grant treatment flow through every investor conversation, every board meeting, and every due diligence process your company will face. Companies that get this right early build compounding advantages: cleaner financials, stronger investor communications, and smoother paths through fundraising and exit.

Understanding your cash burn rate accurately depends on getting these foundations right, as does preparing for any formal audit process.

Building these systems internally can be difficult for early-stage companies that lack a dedicated finance team with life sciences experience. At G-Squared Partners, we work with biotech, pharma, medical device, and diagnostics companies to build the accounting infrastructure that supports their growth — from clinical trial accruals to program-level reporting to audit preparation.

Schedule a discovery call today to learn more about how we can help.